Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM824EG)

Drug Name
COVA322 Drug Info
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 1/2a [1]
Cross-matching ID
TTD Drug ID
DM824EG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Modulator [2]
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-17 (IL17) DTT IL17A 5.188 3.828 3.329 4.615
Tumor necrosis factor (TNF) DTT TNF 5.692 3.07 4.413 1.202
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Psoriasis vulgaris
ICD Disease Classification EA90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.51E-01 0.05 0.27
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02243787) Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
2 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.